Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn MoreBlood-based liquid biopsy refers to the analysis of various biomarkers in the blood to obtain information about the presence, characteristics, and progression of a disease, such as bladder cancer. Alfa Cytology provides comprehensive blood -based analysis services for bladder cancer and assists our customers in achieving their goals.
Bladder cancer (BC) presents a significant challenge worldwide, characterized by late diagnosis, poor prognosis, and low survival rates. Traditional diagnostic and monitoring methods like cystoscopy and tissue biopsy have limitations due to tumor heterogeneity, aggressiveness, high cost, and limited suitability for long-term surveillance. However, in recent years, there has been growing interest in the use of liquid biopsies, particularly blood-based analysis, for the discovery of BC biomarkers.
Fig.1 Overview of clinical examination methods for bladder cancer and laboratory analytical techniques for liquid biopsies. (Li S., et al. 2023)
Liquid biopsies, including blood-based analysis, provide a noninvasive and efficient approach to identify biomarkers for BC. Extensive research has focused on various liquid biopsy biomarkers, and they have shown promising results in several key applications for BC, including early detection, identification of microscopic residual disease, prediction of recurrence, and assessment of treatment response.
Alfa Cytology specializes in providing comprehensive blood-based analysis services for bladder cancer. Our goal is to assist our customers in obtaining crucial information about the presence, characteristics, and progression of the disease. Through our advanced liquid biopsy techniques, we analyze various biomarkers to deliver accurate and actionable insights.
Analyzed Targets | Analysis Methods | Applications | |
---|---|---|---|
|
CTCs | Cell count, genetic profiling by NGS |
|
|
cfDNA/ctDNA | ddPCR, sequencing by NGS | |
|
cfRNA | Measuring mRNA or miRNA by qPCR, NGS or microarray | |
|
Exosomes | Content profiling using qPCR, NGS or microarray | |
|
Metabolomics
proteomic |
GC-MS、LC-MS、NMR |
Real-time Monitoring |
||
Non-Invasive and Patient-Friendly |
Tumor Heterogeneity |
|
Accessibility |
Personalized Medicine |
At Alfa Cytology, we are committed to providing high-quality blood-based analysis services for bladder cancer research. Our experienced team of experts and cutting-edge technologies ensure accurate and reliable results. Contact us today to learn more about our comprehensive services and how we can assist you in achieving your bladder cancer research goals.
Reference
Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.